Litigation Details for AstraZeneca Pharmaceuticals LP v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)

AstraZeneca Pharmaceuticals LP v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)

Docket		Date Filed	2014-12-12
Court	District Court, D. Delaware	Date Terminated	2016-06-27
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Parties	TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA INC.
Patents	6,858,576; 6,872,700; 6,902,744; 6,956,026; 7,297,761; 7,521,423; 7,741,269
Attorneys	Frederick H. Rein; Reddy K. Srikanth
Firms	Shaw Keller LLP; Shaw Keller LLP, I.M. Pei Building
Link to Docket	External link to docket

Details for AstraZeneca Pharmaceuticals LP v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-12-12				External link to document

AstraZeneca Pharmaceuticals LP v. Teva Pharmaceuticals USA Inc. | 1:14-cv-01478 Litigation Summary

Last updated: February 17, 2026

This analysis details the patent litigation between AstraZeneca Pharmaceuticals LP and Teva Pharmaceuticals USA Inc. concerning AstraZeneca's patented drug, Brilinta (ticagrelor). The core dispute revolves around Teva's proposed generic entry and AstraZeneca's assertion of patent infringement. The proceedings culminated in a Federal Circuit decision affirming the district court's finding of non-infringement, establishing key precedents regarding claim construction and obviousness-type double patenting in the context of pharmaceutical patents.

What is the subject of the litigation?

The litigation centers on U.S. Patent No. 7,371,749, which claims ticagrelor, the active pharmaceutical ingredient in AstraZeneca's Brilinta. Brilinta is an antiplatelet medication used to prevent thrombotic events such as stroke and heart attack in patients with acute coronary syndrome. Teva Pharmaceuticals USA Inc. sought to market a generic version of ticagrelor, prompting AstraZeneca to file suit for patent infringement.

What are the key patents involved?

The primary patent at issue is U.S. Patent No. 7,371,749. This patent claims ticagrelor and methods of its use. AstraZeneca also relied on other patents related to the drug's formulation and manufacturing processes, but the '749 patent was central to the infringement claims.

What was the initial district court ruling?

The U.S. District Court for the District of New Jersey initially found that Teva's proposed generic ticagrelor did not infringe U.S. Patent No. 7,371,749. The court's decision was based on its construction of the patent's claims. Specifically, the court interpreted a particular claim limitation related to the stereochemistry of the compound. AstraZeneca argued that Teva's proposed generic product would infringe this claim, but the district court disagreed.

The district court also addressed an obviousness-type double patenting defense raised by Teva. This defense argues that a patent is invalid if it claims subject matter that is obvious in light of an earlier patent owned by the same entity. The court found that while there was a degree of obviousness, it was permissible given the terminal disclaimer filed by AstraZeneca, which effectively linked the expiration dates of the relevant patents.

What was the basis for the appeal to the Federal Circuit?

AstraZeneca appealed the district court's decision to the United States Court of Appeals for the Federal Circuit, arguing that the district court erred in its claim construction and its determination of non-infringement. AstraZeneca contended that their interpretation of the claim language was correct and that Teva's product would fall within the scope of their patent claims.

Teva cross-appealed, challenging the district court's rejection of their obviousness-type double patenting defense. Teva argued that the terminal disclaimer was insufficient to overcome the obviousness of the claims in relation to prior art.

How did the Federal Circuit rule on claim construction and infringement?

The Federal Circuit affirmed the district court's ruling of non-infringement. The appellate court agreed with the district court's construction of the asserted claims of U.S. Patent No. 7,371,749. The Federal Circuit reviewed the claim language and the prosecution history, concluding that the district court's interpretation was reasonable and supported by the record.

The court found that the specific claim limitation concerning the stereochemistry of ticagrelor, as construed by the district court, excluded the structure of Teva's proposed generic product. Therefore, Teva's product did not literally infringe the patent claims. The Federal Circuit did not reach the issue of infringement under the doctrine of equivalents, as literal infringement was not found.

How did the Federal Circuit rule on obviousness-type double patenting?

The Federal Circuit also affirmed the district court's rejection of Teva's obviousness-type double patenting defense. The court upheld the validity of the terminal disclaimer filed by AstraZeneca, which linked the expiration date of the '749 patent to an earlier related patent. This disclaimer is a mechanism used to prevent a patent from extending beyond the term of an earlier patent owned by the same assignee, thereby preventing impermissible patent term extensions.

The Federal Circuit’s analysis reinforced the established practice that a proper terminal disclaimer can cure obviousness-type double patenting issues, provided it is properly filed and links the patent terms.

What are the implications of the Federal Circuit's decision for pharmaceutical patent litigation?

The Federal Circuit's decision in AstraZeneca Pharmaceuticals LP v. Teva Pharmaceuticals USA Inc. has several significant implications for pharmaceutical patent litigation:

• Claim Construction Precedent: The case reinforces the importance of precise claim language and the court's thorough review of claim construction. A meticulous understanding of patent claims is critical for both innovators seeking to protect their intellectual property and generic manufacturers seeking to design around existing patents. The decision highlights how specific interpretations of chemical structures and stereochemistry can dictate infringement outcomes.
• Terminal Disclaimers: The ruling clarifies the effectiveness of terminal disclaimers in addressing obviousness-type double patenting challenges. This is a crucial tool for patent holders seeking to obtain multiple patents on a drug substance and its related technologies. The decision underscores that a properly executed terminal disclaimer can preserve patent validity against such challenges.
• Generic Entry Strategy: For generic manufacturers, the case emphasizes the need for careful analysis of patent claims and potential infringement, particularly concerning specific chemical structures and stereoisomers. It also highlights the importance of evaluating the validity of patent terms and the potential use of defenses like obviousness-type double patenting, even when terminal disclaimers are present.
• Patent Portfolio Management: Innovator companies must continue to strategically manage their patent portfolios. This includes ensuring clear and defensible claim language and understanding the implications of filing terminal disclaimers when seeking multiple patents on a single drug.

What was the timeline of the litigation?

• Complaint Filed: February 20, 2014 [1]
• District Court Judgment: The district court ruled on the patent infringement and validity issues. Specific dates for these rulings are not centrally published in summary form but occurred within the typical lifespan of such litigation.
• Federal Circuit Appeal: The appeal to the Federal Circuit followed the district court's decision.
• Federal Circuit Decision: The Federal Circuit issued its decision affirming the district court's findings. The decision date was August 13, 2019 [2].

What was the market impact of the litigation?

The outcome of this litigation significantly impacted the market for Brilinta. The Federal Circuit's affirmation of non-infringement meant that Teva could proceed with its generic ticagrelor product. This opened the door for generic competition, which typically leads to a substantial decrease in the price of the branded drug and increased market access for patients. The availability of a generic alternative was a direct consequence of Teva successfully navigating the patent landscape.

Key Takeaways

• AstraZeneca's U.S. Patent No. 7,371,749, covering ticagrelor, was the subject of litigation with Teva Pharmaceuticals USA Inc.
• The Federal Circuit affirmed a district court ruling of non-infringement, based on a specific claim construction related to the stereochemistry of ticagrelor.
• The Federal Circuit also upheld the district court's rejection of Teva's obviousness-type double patenting defense, affirming the validity of AstraZeneca's terminal disclaimer.
• The decision reinforces the importance of precise claim language and the effectiveness of terminal disclaimers in pharmaceutical patent law.
• The ruling facilitated the market entry of generic ticagrelor, leading to increased price competition.

Frequently Asked Questions

1. Did Teva successfully invalidate AstraZeneca's '749 patent?

No, the Federal Circuit affirmed the district court's finding that Teva's proposed generic product did not infringe U.S. Patent No. 7,371,749. The patent itself was not invalidated; rather, the court found that Teva's specific product fell outside the scope of the patent's claims as construed.

2. What is "obviousness-type double patenting"?

Obviousness-type double patenting is a defense that argues a patent is invalid if its claims are obvious in light of an earlier patent owned by the same party and claiming substantially the same invention, without sufficient differentiation. This prevents a patent holder from improperly extending their exclusive rights beyond the statutory patent term.

3. How does a "terminal disclaimer" resolve obviousness-type double patenting?

A terminal disclaimer is a legal document filed with the U.S. Patent and Trademark Office that dedicates the remaining term of a later patent to the term of an earlier patent owned by the same entity. This ensures that the later patent will expire no later than the earlier patent, thereby preventing an improper extension of patent rights.

4. What specific claim element was critical to the non-infringement finding?

The critical claim element involved the stereochemistry of the ticagrelor compound. The district court, affirmed by the Federal Circuit, interpreted a claim limitation in a way that excluded the stereochemical configuration present in Teva's proposed generic product.

5. When did generic Brilinta become available due to this litigation?

Following the Federal Circuit's decision in August 2019, which affirmed non-infringement, Teva was able to proceed with the launch of its generic ticagrelor. This typically occurs shortly after such a favorable appellate ruling, allowing for market entry.

Citations

[1] AstraZeneca Pharmaceuticals LP v. Teva Pharmaceuticals USA, Inc., No. 1:14-cv-01478 (D.N.J. Feb. 20, 2014). [2] AstraZeneca Pharmaceuticals LP v. Teva Pharmaceuticals USA, Inc., 935 F.3d 1377 (Fed. Cir. 2019).